Autoject® 2

Autoject® 2

The versatile auto-injector proven across multiple therapy areas

The Owen Mumford Pharmaceutical Services Challenge

Multiple Sclerosis (MS) is a chronic and debilitating inflammatory disease of the central nervous system and currently affecting 2.5 million people worldwide.1 One particular treatment (interferon beta-1b) has shown some impressive results by reducing all-cause mortality by 47% at 21 years.2 Poor patient adherence to interferon beta-1b is often the result of adverse events relating to injectable therapies, like anxiety of injecting,injection site pain (ISP) and injection site reactions (ISRs).1

The Analysis

We created an original injection device for Extavia®, an interferon beta-1b, based on our clinically robust and successful auto-injector platform: the Autoject®2. This platform not only helps minimise ISP and ISRs, but also makes injecting easier and reduces patient anxiety.

Engineering Design

The new device, called ExtaviPro® 30G, is more ergonomically designed; assisting one-handed use and enhancing patient confidence when injecting.3 Constant force spring technology is also incorporated to enhance ease of use.

Patient Responses

The most common reasons for this preference were the ergonomic shape of the device, easy operation, reach and being able to inject one-handed. All these attributes are associated with convenience, which is an important facto that increases adherence and can shift patient preference from one auto-injector to another.3

86% of patients preferred ExtaviPro® 30G over a competitor device

Our Insight

The ExtaviPro® 30G has been shown to solve some aspects of low adherence – and, as a result, increases drug administration. With greater adherence, there are not only better health outcomes for patients, but also better commercial outcomes for pharmaceutical companies.

1. Menzin J et al. Narrative R3view of the Literature on Adherence to Disease-Modifying Therapies among Patients with Multiple Sclerosis. Supplement to JMCP 2013; 19(1-a):S24-33
2. Boeru G et al. ExtaciJect®30G device for subcutaneous self-injection of interferon beta 1-b for multiple sclerosis: a prospective European study. Medical Devices: Evidence Research. 2013; 6:175–184
3. Thakur K et al. Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort® devices. Pragmatic and Observational Research. 2013; 4:19-26


Download Case Study

Contact Us